Oral THC did not impact neuropsychiatric symptoms among patients with dementia

Results from a randomized, double-blind placebo-controlled study indicate that while daily receipt of oral tetrahydrocannabinol was well-tolerated, it did not positively or negatively affect neuropsychiatric symptoms among patients with dementia.Geke A. H. van den Elsen, MD, of the Radboud University Medical Center in Nijmegen, Netherlands, and colleagues randomized 50 patients with dementia to receive 1.5 mg of tetrahydrocannabinol (THC) or placebo three times daily for 3 weeks. THC was in tablet form (Namisol, Echo Pharmaceuticals). Researchers assessed changes in neuropsychiatric symptoms, agitated behavior and aggression, daily living/quality of life and safety at baseline and at 14 and 21 days.